SIGHT — Gensight Biologics SA Share News
0.000.00%
Last trade - 00:00- €17.21m
- €28.38m
- €0.00m
Brief: Gensight Biologics: LUMEVOQ Continues To Show Promise As Novel Therapy For ND4-LHON
Brief: Gensight Biologics Announces Publication Of Lumevoq Results
Brief: Gensight Biologics Secures €35 Million Credit Facility From EIB For Launch Of Lumevoq® In Europe
Brief: Gensight Biologics 9-Month Cash Position At Eur 19.9 Mln
Brief: Gensight Biologics Announces Successful Completion Of Lumevoq® Engineering Batch Validating Implemented Corrective Actions
Brief: GenSight Biologics H1 Net Loss Widens To 10.7 Million Euros
Brief: GenSight Biologics Publishes 5 Years’ Data On LUMEVOQ®
Brief: Gensight Biologics End-March Cash At 36 Million Euros
Brief: GenSight Biologics Granted Six-Month Extension In LUMEVOQ European Regulatory Review
Brief: Gensight Biologics FY Net Loss Narrows To EUR 28.6 Mln
Brief: Gensight Biologics Provides Update On Lumevoq Manufacturing Timeline
Brief: Gensight Biologics Appoints Sissel Rodahl As Senior VP Of Commercial Operations
Brief: GenSight Biologics Says Clinically Meaningful Vision Improvement Maintained 4 Years After One-Time LUMEVOQ Treatment
Gensight Biologics slumps after FDA delays LUMEVOQ roll-out
Brief: Gensight Biologics End-December Cash And Cash Equivalents At 44.3 Million Euros
Brief: GenSight Says Efficacy, Safety Of Bilateral LUMEVOQ Injections
Brief: GenSight Announces Publication Of Study Reporting Presence Of LUMEVOQ Vector DNA In Contralateral Eyes After Unilateral Injection
Brief: Gensight Biologics Announces Extension Of Day 120 Clock Stop Of LUMEVOQ
Brief: Gensight Biologics 9-Month Cash And Cash Equivalents At 49.1 Million Euros